ECM
KPTI icon

Element Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Element Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-789
Closed -$201K – 953
2018
Q2 		$201K Buy
+789
New +$195K 0.01% 723

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Element Capital Management's KPTI Position: Q3 2018 in Review

Element Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2018, closing a stake of 789 shares — an estimated $201K sold.

Element Capital Management first reported a position in KPTI in Q2 2018 and held it in 1 quarter. The position peaked at $201K in Q2 2018. 119 funds tracked by Wall St. Rank hold KPTI as of Q3 2018.

  • Element Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Element Capital Management sold 789 Karyopharm Therapeutics shares in Q3 2018, an estimated $201K.
  • Element Capital Management first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 1 quarter.
  • Element Capital Management's Karyopharm Therapeutics position peaked at $201K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2018.

Based on Element Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.